Author Index

Articles appearing on AJKD Electronic Pages are referred to by journal number, a colon, the letter E, and a number.
Page references to Supplement 1 (January 2007), Supplement 2 (February 2007), and Supplement 3 (March 2007) are preceded, respectively, by S1:, S2:, and S3:.

Abbas, N.A., 507
Abbott, K.C., 801
Abdullah, H., 127
Acheampong, J., 394
Adeyemo, A.A., 394
Afshinnia, F., 227
Agyenim-Boateng, K., 394
Akiba, T., 426
Akman, C., 143
Alchi, B., 499
Ali, S., 365
Alon, U.S., 650
Alscher, D.M., 452
Altiparmak, M.R., 143
Alvestrand, A., 237
Ambroso, G., 753
Amdahl, M., 814
Amigues, L., 99
Amoah, A., 394
Amoroso, A., 69
Anderson, J.E., 581
Andreoli, S.P., 175
Apaydin, S., 143
Arzouk, N., 862
Askepidis, N., 540
Astor, B.C., 37
Ataman, R., 143
Audard, V., 710
Auron, A., 650
Axelsson, J., 237

Bacher, J., 1:E11
Bailie, G.R., 426
Baines, L., 301
Bakris, G.L., 12
Bammens, B., 642
Banasik, M., 824
Banfi, G., 69
Bárány, P., 237
Baron, J.P., 717
Barrou, B., 862
Baskin-Bey, E.S., 284
Bauling, P., 517
Bayer, A.S., 401
Beccaria, L., 91
Beddhu, S., 356
Bedossa, P., 705
Begum, M., 208
Bellantuono, R., 91
Beltrame, A., 69
Benador, N., 814
Benalia, H., 862
Bensman, A., 158
Beraud, J.-J., 99
Berbano, E.P., 801
Berbiche, D., 245
Berthier-Schaad, Y., 118
Bettinelli, A., 91
Beyene, J., 674
Bhat, A., 477
Bianchetti, M.G., 91
Biegger, D., 452
Bilous, R.W., 194
Biondi-Zoccai, G.G.L., 56
Blagg, C.R., 482
Blanchin, S., 598
Blázquez, J., 854
Blouin, J., 323
Blowey, D.L., 650
Boehm, D., 1:E11
Boffa, M.B., 432
Bolayirli, M., 143
Bonso, E., 330
Booth, S.L., 432
Borsa, N., 91
Bourry, E., 862
Bove, T., 56
Bragg-Gresham, J.L., 426
Braun, N., 452
Brousse, N., 793
Brunori, G., 569
Bunnapradist, S., 180
Burger, U., 194
Butani, L., 3:xlix
Buzina, W., 701

Cabiddu, G., 753
Calabrese, R., 91
Calabrò, M.G., 56
Calò, L.A., 330
Calverley, D.C., 127
Canaud, B., 99
Cancarini, G.C., 569
Cantin, I., 245
Capobianco, C., 664
Carrero, J.J., 237
Chacón, C., 854
Chadban, S.J., 301
Chadow, H.L., 227
Chan, D., 776
Chan, Y.-H., 547
Charytan, D., 409
Chau, K.F., 547
Chen, G., 394
Chen, H.-C., 626
Chen, J.L.T., 83
Chen, M., 607
Chen, Y., 394
Cheng, C.J., 693
Cheung, A.K., 356
Cheung, A.L., 401
Cho, M.E., 310
Choi, K.S., 547
Chonchol, M., 373
Chou, S.-Y., 227
Chow, K.-M., 524
Chuang, L.-Y., 626
Chung, K.-Y., 524
Cifarelli, M., 664
Claes, K., 642
Coca, S.G., 517
Cohen, A.J., 37
Collins, A.J., 135, 175
Colombo, V., 69
Como, G., 569
Comotti, C., 69
Confalonieri, R., 69
Cook, T., 373
Coresh, J., 118, 217, 831
Corneille, L., 245
Couser, W.G., 349
Cruz, J.M., 426

Dahan, K., 793
Dahut, W.L., 186
D'Altri, C., 763
Danovitch, G.M., 180
Dasgupta, A., 656
Daugas, E., 158
Davison, J.M., 729
Davison, S.N., 27
Day, A.G., 432
de Alvaro, F., 194
De Biase, V., 569
DeFilippi, C., 409
Dejagere, T., 642
de Jong, S., 533
Deleuze, S., 99
Del Giudice, A., 753
De Luca, M., 56
Desvaux, D., 710
Devereux, R.B., 208
Di Belgiojoso, G.B., 69

Diez Roux, A.V., 217
Di Paolo, S., 462
Dluhy, R.G., 566
Dogra, G., 776
Dogra, S., 301
Don, B.R., 477
Doumatey, A., 394
Dragon-Durey, M.-A., 323
DuBose, T., 175

Ebben, J.P., 135
Edefonti, A., 91
Egbuna, O., 851
Eghan, B.A. Jr., 394
Eknoyan, G., 865
El Karoui, K., 710
Elsayed, E., 183
El-Shahawy, M., 127
Eng, J., 634
Erek, E., 143
Eris, J., 301
Evenepoel, P., 642

Fabsitz, R.R., 208
Fakhouri, F., 705
Fasanmade, O., 394
Felipe, C., 854
Fidalgo, A., 854
Fink, N., 118, 831
Fischbach, M., 323
Fischer, K.-G., 2:xlix
Fishbane, S., 736
Fissell, R.B., 426
Fornasieri, A., 69
Fox, C.S., 37
Franco, V., 569
François, H., 158
Francos, M., 854
Frankenfield, D.L., 276
Freeman, D.J., 109
Fremeaux-Bacchi, V., 323
Fridman, W.H., 323
Fritz, P., 452
Fujino, Y., 417

Gaber, L.W., 153
Gammaro, L., 753
Gao, Y., 607
Garcarek, J., 824
Garibotto, G., 569
Gasque, P., 598
Gejyo, F., 499
Gemery, J.M., 401
George, B.A., 2:E23
Gerke, P., 2:xlix, 6:xlix
Gesualdo, L., 462
Ghossein, C., 656
Giachino, O., 69
Gilbertson, D.T., 135
Gillespie, B.W., 426
Glickman, J.D., 1:E7
Göbel, H., 2:xlix, 6:xlix
Goldberg, R., 83
Goldberger, J., 656
Goldstein, S.L., 814
Gore, J., 83
Grandaliano, G., 664
Greenbaum, L.A., 814
Greene, E.L., 552
Greenwell, M.W., 383
Gregorini, G., 753
Groth, C., 2:xlix
Grünfeld, J.-P., 705
Gubler, M.C., 793
Guh, J.-Y., 626
Guiochon-Mantel, A., 705
Gunsburg, D.Z., 227

Hacini, S., 862
Hadchouel, M., 705
Haddad, M.N., 3:xlix
Hak, L.E., 615
Hara S., 744
Hayden, J.A., 674
Heimbürger, O., 237
Heiss, G., 217
Hellmark, T., 710
Hendriksz, T.R., 615
Higa, Y., 744
Hoffman, H.M., 477
Hofmann, L.V., 5:xliii
Horina, J., 701
Hoshino, J., 744
House, A.A., 109
Howard, C.S., 517
Hricik, D.E., 732
Hsu, Y.-J., 693
Huang, H., 394
Hurley, J.K., 310
Hyre, A.D., 37

Imanishi, Y., 417
Imbasciati, E., 753
Inaba, M., 417, 440
Ioannidis, H., 540
Irish, A., 301, 776
Ishimura, E., 417
Ito, A., 440
Ix, J.H., 365
Izzedine, H., 862

Jaar, B.G., 831
Jacquet, A., 705
Jamal, S.A., 674
Janczak, D., 824
Jeanpierre, C., 793
Jefferys, A., 301
Jeunemaitre, X., 862
Jia, X., 294
John, R.I., 507
Johnson, S., 851
Johnson, T., 394

Kahveci, A., 143
Kalantar-Zadeh, K., 581
Kamal, M., 793
Kanganas, C., 301
Kao, W.H.L., 118
Katori, H., 744
Kaufman, J.S., 217
Kenny, C., 507
Kerr, P.G., 533
Khoprasert, S., 841
Khositseth, S., 841
Khosla, N., 12
Kim, H., 318
Kitatani, K., 417
Kjekshus, J., 373
Klag, M.J., 831
Klak, R., 824
Klinger, M., 824
Klouche, K., 99
Knowler, W.C., 208
Kohno, K., 417
Komninos, J., 91
Konduri, V., 634
Kopp, J.B., 310
Koschinsky, M.L., 432
Kovesdy, C.P., 581
Krajewska, M., 824
Krane, N.K., 336
Krane, V., 267
Krause, R., 701
Kremers, W., 284
Krieter, D.H., 267
Kshirsagar, A.V., 217
Kühn, W., 2:xlix
Kuntz, R.E., 409
Kuo, H.-W., 46
Kurkus, J., 471
Kurokawa, K., 426
Kusztal, M., 824
Kuypers, D., 642
Kwan, B.C.-H., 524
Kwan, M., 682
Kwok, P.C.-H., 547
Kyrieleis, H.A.C., 592

Lager, D., 552
Laliberté, M.-C., 245
Lalonde, L., 245
Lamarre, D., 245
Lamb, E.J., 507
Landoni, G., 56
Lang, P., 710
Lashley, K., 394
Lau, K.K., 3:xlix
Laville, M., 194
Lederer, E., 162
Lee, E.T., 208
Lessard, D., 83
Letachowicz, W., 824
Leung, C.-B., 524
Levey, A.S., 1, 175, 831

Levin, N.W., 831
Levtchenko, E.N., 592
Lewin, M., 552
Li, C.S., 547
Li, P.K.-T., 524
Li, S., 294
Liang, K.V., 552
Liapis, H., 4:xlix
Lin, J.-L., 1:E1
Lin, S.-H., 693
Lindenfeld, J., 373
Lindergård, B., 471
Lindheimer, M.D., 729
Lindholm, B., 237
Liu, A.Y.-L., 547
Liu, L., 786
Lloyd-Jones, D.M., 656
López-Valdés, E., 854
Lord, A., 245
Loverre, A., 664
Lui, S.-F., 682

Mack, W.J., 127
Madziarska, K., 824
Maekawa, K., 417
Maeno, Y., 417
Mangold, T.M., 383
Mann, J.F.E., 267
Manno, C., 69, 763
Mariaud de Serre, N.P., 793
Marrone, D., 664
Martín, J., 854
Martín, R., 854
März, W., 267
Mason, N.A., 426
Matsuo, S., 598
Mattingly, S., 814
Mauri, L., 409
McClellan, W.M., 276
McDowell, L.L., 717
McManus, D., 365
Medendorp, S., 656
Melnick, J.Z., 814
Memoli, B., 664
Menon, V., 3
Menouer, S., 323
Miller, D.V., 859
Miller, L.M., 432
Miskulin, D.C., 257
Mizumo, M., 598
Montalvo, J., 656
Moriconi, L., 69
Morton, A.R., 432
Muntner, P., 37
Murashima, M., 1:E7
Murtaugh, M.A., 356
Musharaf, G., 650

Nakanishi, S., 744
Narayan, R., 801
Narita, I., 499
Neff, R.T., 801
Neumann, H.P.H., 1:E11
Ng, K., 682
Nishi, S., 499
Nishikawa, K., 598
Nishizawa, Y., 417
Noël, L.H., 705, 710, 793
Nomura, K., 744
Noordhof, C., 432
Nordfors, L., 237
Normandeau, M., 245
Noureddin, M., 127
Nyberg, S.L., 284
Nykvist, M., 471

O'Donoghue, D., 194
Oei, L.S., 552
Okafor, G., 394
Okuno, S., 417
Oli, J., 394
Olschewski, H., 701
Olschewski, M., 267
Opastirakul, S., 841
Ouseph, R., 162

Padiyar, A., 732
Pagkalos, E., 540
Palatini, P., 330
Pani, A., 69
Paraíso, V., 854
Pardon, A., 710
Paredes, A., 814
Parfrey, P.S., 352
Parikh, C.R., 186, 517
Park, J., 318
Parotto, E., 330
Parrinello, G., 569
Pasquali, S., 69
Passman, R., 656
Pavlakis, M., 851
Pazarloglou, M., 540
Pedersen, T.R., 373
Pela, I., 91
Perazella, M.A., 153
Perkins, R.M., 801
Pertosa, G., 664
Pessina, A.C., 330
Peuksungnern, R., 841
Pilkey, R.M., 432
Plantinga, L., 118, 831
Polkinghorne, K., 301
Ponzetto, A., 69
Porazko, T., 824
Port, F.K., 294
Powe, N.R., 831
Price, C.P., 507
Provenzano, R., 175
Prud'homme, L., 245

Qi, L., 786
Quarenghi, M.I., 69
Qureshi, A.R., 237

Ramirez, S., 426
Ramkumar, N., 356
Ranieri, E., 462
Ranucci, M., 56
Rao, P.S., 294
Ravani, P., 753
Remillard, B.D., 401
Remy, P., 710
Rieg, S., 6:xlix
Ritz, E., 194, 267
Roccatello, D., 69
Rocco, M.V., 276
Rodríguez-Berzosa, F., 854
Rohatgi, R., 634
Ronco, P., 158
Roob, J., 701
Rossi, D., 69
Rossini, M., 763
Rotimi, C., 394
Rustichelli, R., 69

Sahali, D., 710
Salusky, I.B., 814
Sanlaville, D., 323
Santostefano, M., 91
Sarafidis, P.A., 12
Saran, R., 294
Sariyar, M., 143
Sarkar, S.R., 153
Sartori, M., 330
Savoldi, S., 69
Sawa, N., 744
Sawyers, E.S., 801
Schalling, M., 237
Schaubel, D.E., 294
Schena, F.P., 664, 763
Schena, P.F., 462
Scherhag, A., 194
Schifftner, T., 517
Schmid, C.H., 3
Schwetz, I., 701
Sea, M.M.-M., 682
Sedlacek, M., 401
Segelmark, M., 471
Sekhon, I.S., 859
Semplicini, A., 330
Serdengecti, K., 143
Sethi, S., 552, 859
Seyahi, N., 143
Shah, S., 349
Shiang, J.-C., 693
Shin, G.-T., 318
Shlipak, M., 365
Shoham, D.A., 217
Siemes, C., 615
Simon, S., 650
Simone, S., 664
Singh, A., 153
Sirikanerat, A., 841

Smith, M.W., 118
Sogawa, Y., 744
Sosnov, J., 83
Spaia, S., 540
Speckman, R.A., 276
Spence, J.D., 109
Spitalewitz, S., 227
Sqalli, T., 705
Srivastava, T., 650
Steffl, D., 2:xlix
Stenvinkel, P., 237
Strippoli, G.F.M., 763
Stubanus, M., 6:xlix
Su, Y., 432
Suliman, M.E., 237
Sutherland, W.H.F., 533
Suwabe, T., 744
Syrén, M.-L., 91
Sze, D.Y., 5:xliii
Szeto, C.-C., 524

Takaichi, K., 744
Takei, R., 744
Takemoto, F., 744
Tarantino, A., 69
Tedeschi, S., 91
Teitelbaum, I., 517
Tentori, F., 257
Teutonico, A., 462
Thongnoppakhun, W., 841
Thornton, B.D., 477
Tiao, M.-M., 46
Tighiouart, H., 257
Tolley, E.A., 383
Tomaszewski, J., 1:E7
Tominaga, Y., 440
Tonelli, M., 8
Torgunrud, C., 27
Torres, D., 763
Torres, V.E., 725
Toto, R., 2:E23
Touchard, G., 710
Trafidlo, E., 824
Tsai, J.-F., 626
Tsai, S.-S., 46
Tumlin, J.A., 56

Ubara, Y., 744
Uhlig, K., 3
Umans, J.G., 208
Urquhart, B.L., 109

Vaithalingham, I., 533
van Bommel, E.F.H., 615
van den Bosch, M.A., 5:xliii
van der Veer, S.J., 615
Vanrenterghem, Y., 642
Varyemezis, V., 540
Vekemans, M., 323
Verhamme, P., 642
Vickery, S., 507
Vidal-Trecan, G.M., 801
Viola, B.F., 559
Viprakasit, V., 841
Vupputuri, S., 217

Wald, R., 257
Walker, R., 301, 533
Wall, B.M., 383
Walz, G., 2:xlix, 6:xlix
Wang, A.Y.-M., 682
Wang, F., 786
Wang, H., 786
Wang, H-y., 607
Wang, S., 786
Wang, S-x., 607
Wanner, C., 267
Warady, B.A., 650
Wasse, H., 276
Watorek, E., 824
Wattanasirichaigoon, D., 841
Watts, G., 776
Webb, M.C., 507
Weiner, D.E., 1, 183
Wetzels, J.F.M., 592
Weyde, W., 824
Whooley, M.A., 365
Williams, L.A., 814
Williams, S.M., 533
Witasp, A., 237
Wizemann, V., 426
Wong, K.M., 547
Wongbenjarat, K., 841
Woo, J., 682
Wu, I.-W., 1:E1
Wu, M.-Y., 1:E1
Wu, S., 186
Wu, S.-S., 1:E1
Wyatt, C., 634

Xu, J., 208

Yajima, A., 440
Yamakawa, T., 417
Yang, C.-Y., 46
Yang, S.-S., 693
Yang, Y., 786
Yarzebski, J., 83
Yeh, J., 208
Yenchitsomanus, P-t., 841
Yeo, F.E., 801
Yim, H., 318
Young, D.O., 4:xlix
Young, E.W., 426
Yu, F., 607
Yuan, C.M., 801

Zager, P.G., 257
Zangrillo, A., 56
Zeng, D., 217
Zhang, B., 786
Zhang, L., 118, 786
Zhao, F., 786
Zhao, M-h., 607
Zhou, J., 394
Zhou, X.J., 2:E23
Zhu, X., 186
Zoghby, Z., 859
Zou, W-z., 607
Zubani, R., 569

Subject Index

Articles appearing on AJKD Electronic Pages are referred to by journal number, a colon, the letter E, and a number.
Page references to Supplement 1 (January 2007), Supplement 2 (February 2007), and Supplement 3 (March 2007) are preceded, respectively, by S1:, S2:, and S3:.

Abdominal aortic calcification, mortality in maintenance hemodialysis and, 412–425
Acute myocardial infarction with kidney disease, use of DNR orders for, 83–90
Acute renal failure (ARF)
in critically ill patients, fenoldopam for, 56–68
morbidity/mortality in burn patients and, 517–523

use of soft silicone tunneled femoral dialysis catheters for, 99–108
Adolescents, with chronic kidney disease and diabetes mellitus, S2:120–130
ADPKD. *See* Autosomal dominant polycystic kidney disease
Advance care planning, for end-stage renal disease, 27–36
Age, prolonged CVC dependence in ESRD and, 276–283
Alagille syndrome, diagnosis during adulthood, 705–709
Albuminuria
management in normotensive diabetic kidney disease patients, S2:109–115
normal range, risk of cardiovascular disease and death in American Indians and, 208–216
Aldosteronism, prevalence and physiological consequences of, 566–568
Alpha-blockers, for proteinuria patients, 12–26
American Indians, cardiovascular disease and death risk with normal range albuminuria in, 208–216
Amyloidosis, in familial cold autoinflammatory syndrome, IL-1 receptor antagonist for, 477–481
Anakinra, for amyloidosis in familial cold autoinflammatory syndrome, 477–481
Analgesic nonuse, CKD risk in Taiwanese adults on herbal therapy and, 626–633
ANCA-positive vasculitis, propylthiouracil-associated, clinical and pathological features of, 607–614
Anemia
hemoglobin target level for diabetics with, 194–207
iron management in nondialysis-dependent CKD, 736–743
long-term survival on hemodialysis, 471–476
posttransplantation, not solely attributed to impaired kidney function, 301–309
Angiogenesis inhibitors, risk of proteinuria and hypertension with bevacizumab, 186–193
Angiotensin receptor blockers
for proteinuria patients, 12–26
increased use after eGFR reporting in primary care clinics, 634–641
Angiotensin-converting enzyme inhibitors
fetal and maternal pregnancy outcomes in CKD, 753–762
for proteinuria patients, 12–26
increased use after eGFR reporting in primary care clinics, 634–641
Anion exchanger 1 gene mutations, in distal renal tubular acidosis of children from Thailand, 841–850
Aniridia, small glomeruli in WAGR syndrome, 793–800
Anti-tubular basement membrane antibodies, in rapidly progressive glomerulonephritis, 710–716
Anti-VEGF antibody, proteinuria and hypertension associated with, 186–193
Anticoagulation, regional citrate *vs.* heparin-coated polyacrylonitrile membranes in patients with bleeding risk, 642–649
Anticytokines, for renal amyloidosis in familial cold autoinflammatory syndrome, 477–481
Antihypertensive drugs, for proteinuria patients, 12–26
Antineutrophil cytoplasmic antibody-positive vasculitis, propylthiouracil-associated, clinical and pathological features of, 607–614
Apolipoprotein E, subclinical vitamin K deficiency in hemodialysis patients and, 432–439
ARF. *See* Acute renal failure
Arterial compliance in CKD, effect of statin and fibrate therapy on, 776–785
Arteriovenous fistula
radial artery-perforating for hemodialysis, 824–830
stenosis, local activation of IL-6 and, 664–673
Ascorbic acid intake, of Chinese patients during CAPD, cardiac disease and, 682–692
Aspergillus oryzae peritonitis, in continuous ambulatory peritoneal dialysis, 701–704
Aspirin, decreased frequency of *Staphylococcus aureus* bacteremia in HD patients with tunneled catheters and, 401–408
Atherosclerosis
and CKD risk, socioeconomic status and, 217–226
platelet FcgRIIA receptor surface expression in ESRD and, 127–134
total plasma homocysteine clearance during HD, effect of IV mensa on, 109–117
Atorvastatin, effect on arterial function in chronic kidney disease, 776–785
Autonomic nervous system, hypotension in Bartter/Gitelman syndromes and, 330–335
Autosomal dominant polycystic kidney disease (ADPKD)
liver disease, symptoms and treatments for, 725–728
percutaneous transcatheter hepatic artery embolization for liver cysts in, 744–752

Baroreflex, autonomic nervous system function in hypotension of Bartter/Gitelman syndromes and, 330–335
Bartter syndrome
biallelic mutations in chloride channel gene *CLCNKB*, 91–98
hypotension, autonomic nervous function in, 330–335
Behavioral self-management, for diabetes mellitus with CKD, S2:131–138
Beta-blockers, for proteinuria patients, 12–26
Bevacizumab, proteinuria and hypertension associated with, 186–193
Bleeding, regional citrate anticoagulation *vs.* heparin-coated polyacrylonitrile membranes for high-risk HD patients, 642–649
Blood pressure control
goals, in proteinuria management, 12–26
improvement after eGFR reporting in primary care clinics, 634–641
Blood volume, hypocalciuria in Gitelman syndrome and, 693–700
BMD. *See* Bone mineral density
Body mass index, mortality in nondialysis-dependent men with CKD, 581–591
Bone disease, long-term survival on hemodialysis, 471–476
Bone mineral density (BMD)
cortical bone loss in secondary hypoparathyroidism reduced by minimodeling, 440–451
lower levels in ESRD patients with fractures, 674–681
Burn injuries, contribution of acute kidney injury to morbidity and mortality in, 517–523

C-reactive protein serum levels, *CRP* gene variation and, 118–126
Calcifications
abdominal aortic, mortality in maintenance hemodialysis and, 412–425
radial artery, Gracz fistula for hemodialysis with, 824–830
Calcium
impact of KDOQI guidelines on hemodialysis patients, 257–266
renal reabsorption in Gitelman syndrome, hypovolemia and, 693–700
Calcium channel blockers, for proteinuria patients, 12–26
Cancer
bevacizumab-associated proteinuria and hypertension, 186–193
incidence before and after kidney transplantation, 732–735
CAPD. *See* Continuous ambulatory peritoneal dialysis
Cardiac morphology, renal function in diastolic heart failure with CKD and, 227–236
Cardiac troponins, increase in nondialysis patients with CKD, 507–516
Cardiovascular disease
comorbidity, prolonged CVC dependence in ESRD and, 276–283
increased coronary artery calcification and decreased GFR in living kidney donors and, 143–152
nutrient intake of Chinese patients during CAPD and, 682–692
platelet FcgRIIA receptor surface expression in ESRD and, 127–134
risk
CRP gene variation and, 118–126
with normal range albuminuria in American Indians, 208–216
total plasma homocysteine clearance during HD, IV mensa effect on, 109–117
Cardiovascular functional status, cytostatin C, HRR and exercise capacity in coronary heart disease and, 365–372
Cardiovascular mortality
abdominal aortic calcification in maintenance HD and, 412–425
in asymptomatic HD patients, distribution of coronary artery disease in, 409–416
in chronic renal insufficiency, secondary prevention by simvastatin, 373–382
outcome of maintenance HD for type 2 diabetes, effects of dialyzer membrane characteristics on, 267–275
risk with normal range albuminuria in American Indians, 208–216
Carotid artery intima-media thickness, and early-stage CKD in Chinese population, 786–792
Catheters
hemodialysis
central venous, prolonged dependence in ESRD and, 276–283
soft silicone tunneled femoral, for ARF, 99–108
tunneled, aspirin-associated decrease in *Staphylococcus aureus* bacteremia with, 401–408
peritoneal dialysis multipurpose drainage *vs.* Tenckhoff for infants and children, 650–655
Children
in Thailand with distal renal tubular acidosis, *AE1* gene mutations and, 841–850
multipurpose drainage catheter for acute peritoneal dialysis of, 650–655
on hemodialysis, IV paricalcitol for secondary hyperparathyroidism in, 814–823
with chronic kidney disease and diabetes mellitus, S2: 120–130
with minimal change nephrotic syndrome, long-term outcome after cyclophosphamide, 592–597
Chinese population
carotid artery intima-media thickness in early-stage CKD and, 786–792
nondiabetic PD patients, new-onset hyperglycemia in, 524–532
with propylthiouracil-associated ANCA-positive vasculitis, 607–614
Chloride channel gene *CLCNKB*, biallelic mutations in, 91–98
Cholestasis, Alagille syndrome diagnosis during adulthood and, 705–709
Chronic kidney disease (CKD)
Alagille syndrome diagnosis during adulthood, 705–709
and atherosclerosis risk, socioeconomic status and, 217–226
conceptual model of, 175–176
detection of, 177
early-stage, carotid artery intima-media thickness in Chinese population and, 786–792
effect of statin and fibrate therapy on arterial function in, 776–785
eGFR rate reporting effect on outpatient care, 634–641
fetal and maternal outcomes of pregnancy and, 753–762
in nephrotic syndrome with hepatitis C, 717–720
increased coronary artery calcification and decreased GFR in living kidney donors and, 143–152
long-term hemodialysis, early development of, 482–496
mortality in nondialysis-dependent men, lower body mass index and, 581–591
nephrology core curriculum, 162–171
nondialysis-dependent patients
cardiac troponin I increase in, 507–516
iron management in, 736–743
prediction of mortality in spinal cord injury patients and, 383–393
pregnancy and, 729–731
prevention and research, 178
reclassifying as CHD risk equivalent, 8–11, 37–45
risk, in adult Taiwanese on herbal therapy not using analgesics, 626–633
simvastatin prevention of all-cause mortality and major coronary events in, 373–382
stage 5. *See* End-stage renal disease
surveillance, 177–178
synergistic effect of metabolic syndrome and inflammation in, 356–364
use of over-the-counter and natural products in, 245–256
visfatin association with inflammation in, 237–244

with diabetes mellitus. *See* Diabetes mellitus, with chronic kidney disease
with hypertension and diastolic heart failure, left ventricular geometry and, 227–236
Cigarette smokers, renal lesions mimicking chronic thrombotic microangiopathy and hypertensive lesions in, 552–559
Cinacalcet, *vs.* parathyroidectomy for hyperparathyroidism in ESRD, 801–813
Citrate anticoagulation, regional *vs.* heparin-coated polyacrylonitrile membranes in patients with bleeding risk, 642–649
Clinical performance measures, relationship to long-term HD outcomes, 352–355
Clinical research studies, recommendations for reporting, 3–7
Cocaine abuse, loin pain and renal vein thrombosis from, 859–861
Cognitive impairment, in hemodialysis patients, 183–185
Collagenofibrotic glomerulopathy, clinicopathologic overview of, 499–506
Complement
C3a receptor, in glomeruli in lupus nephritis, 598–606
severity of atypical HUS, MCP mutation and uniparental isodisomy and, 323–329
Complications
after pacemaker implantation in ESRD patients, 656–663
Aspergillus oryzae peritonitis in continuous ambulatory peritoneal dialysis, 701–704
from cocaine, venous thrombosis and loin pain as, 859–861
peritoneal dialysis, multipurpose drainage catheter for infants and children, 650–655
soft silicone tunneled femoral dialysis catheters for ARF and, 99–108
veno-calceal fistula related to ureteric structure in kidney allograft dysfunction, 547–551
Computed tomographic scan, long-term outcome of prednisone for idiopathic retropertioneal fibrosis, 615–625
Conn syndrome, prevalence and physiological consequences of, 566–568
CONSORT, recommendations for reporting RCTs, 3
Continuous ambulatory peritoneal dialysis (CAPD)
Aspergillus oryzae peritonitis in, 701–704
nutrient intake of Chinese patients, cardiac disease and, 682–692
Coronary artery calcification, decreased GFR in living kidney donors and, 143–152
Coronary artery stenosis, distribution in relation to mortality in asymptomatic HD patients, 409–416
Coronary heart disease
association of cytostatin C, exercise capacity and HRR in, 365–372
distribution in relation to mortality in asymptomatic HD patients, 409–416
inflammation and metabolic syndrome in CKD and, 356–364
Coronary heart disease risk equivalent, reclassifying CKD as, 8–11, 37–45
Cortical bone loss, in secondary hypoparathyroidism reduced by minimodeling, 440–451
Cost utility analysis, of hyperparathyroidism management in ESRD, 801–813
Cost-effectivness analysis, recommendations for reporting, 5
Creatinine
genome scan in West Africans for linkage of renal function phenotypes with type 2 diabetes, 394–400
vs. cytostatin C in predicting impaired kidney function in CHD, 365–372
Creatinine clearance
genome scan in West Africans for linkage of renal function phenotypes with type 2 diabetes, 394–400
posttransplantation anemia not solely attributed to impaired kidney function, 301–309
prediction of mortality in spinal cord injury patients and, 383–393
Critical illness, acute kidney injury in burn patients and, 517–523
Cryoglobulinemic glomerulonephritis, hepatitis C virus-related, 69–82
Crystalluria, acute oxalate nephropathy associated with Orlistat, 153–157
Cyclophosphamide, long-term outcome for children with minimal change nephrotic syndrome and, 592–597
Cytokines
impact of standard high-flux polysulfone *vs.* Helixone membranes on, 533–539
visfatin association with inflammation in CKD, 237–244
Cytostatin C, association with poor exercise capacity and heart rate recovery in CHD, 365–372

Decision analyses, recommendations for reporting, 5
Defibrillator implantation, complication rate in ESRD patients, 656–663
Diabetes mellitus
CHD risk equivalent listing and, 8–11
maintenance hemodialysis outcome, effects of dialyzer membrane characteristics on, 267–275
target level for hemoglobin correction for anemia in, 194–207
type 2, genome scan for linkage of renal function phenotypes in West Africans, 394–400
with chronic kidney disease
behavioral self-management for, S2:131–138
dyslipidemia management and, S2:88–94
evidence-based approach, guidelines for, S2:148–154
hyperglycemia management and, S2:62–73
hypertension management and, S2:74–87
in special populations, S2:120–130
multifaceted intervention for, S2:116–119
nutritional interventions for, S2:95–107
Diabetic kidney disease (diabetic nephropathy)
normotensive, albuminuria management in, S2:109–115
screening and diagnosis of, S2:42–61
target level for hemoglobin correction for anemia in, 194–207
Diagnostic accuracy studies, recommendations for reporting, 4–5

Dialysis dose, soft silicone tunneled femoral dialysis catheters for ARF and, 99–108
Dialysis Outcomes and Practice Pattern Study (DOPPS), diuretic use, residual renal function and mortality in HD patients, 426–431
Dialyzer membranes
  heparin-coated polyacrylonitrile *vs.* regional citrate anticoagulation in patients with bleeding risk, 642–649
  outcome of patients with type 2 diabetes on maintenance HD and, 267–275
  standard high-flux polysulfone *vs.* Helixone on inflammatory markers, 533–539
Diastolic heart failure, with hypertension and CKD, left ventricular geometry and, 227–236
Diet
  cardiac disease in Chinese CAPD patients and, 682–692
  very low protein. *See* Very low protein diet
Distal renal tubular acidosis, associated with *AE1* gene mutations in children from Thailand, 841–850
Diuretics
  for proteinuria patients, 12–26
  in hemodialysis patients, residual renal function, mortality and, 426–431
Do-not-resuscitate orders (DNR), for kidney disease patients with acute myocardial infarction, 83–90
DOPPS (Dialysis Outcomes and Practice Pattern Study), diuretic use, residual renal function and mortality in HD patients, 426–431
Drug-related problems
  sirolimus nephrotoxicity, focal segmental glomerulosclerosis and, 310–317
  use of over-the-counter and natural products in chronic renal insufficiency, 245–256
Dyslipidemia
  and diabetes management in chronic kidney disease, S2: 88–94
  effect of statin and fibrate therapy on arterial function in chronic kidney disease, 776–785

Elderly
  postponement of dialysis, safety and efficacy of very low-protein diet for, 569–580
  prevalence of chronic kidney disease in Taiwan and, 46–55
  with CKD and diabetes mellitus, S2:120–130
Encapsulating peritoneal sclerosis, fibrosis in peritoneal of PD patients, peritoneal mast cells and, 452–461
End-of-life care
  advance care planning for end-stage renal disease, 27–36
  use of DNR orders in AMI patients with kidney disease, 83–90
End-stage renal disease (ESRD)
  advance care planning for, 27–36
  complication rate after pacemaker implantation, 656–663
  CRP gene variation, CRP serum levels and, 118–126
  early, intermediate and long-term risk factors for mortality, 831–840
  fetal and maternal outcomes of pregnancy and, 753–762
  hyperparathyroidism management, cost utility analysis of, 801–813
  long-term hemodialysis, early development of, 482–496
  platelet FcgRIIA receptor surface expression in, 127–134
  predictors of prolonged CVC dependence, 276–283
  secondary hyperparathyroidism, IV paricalcitol for children on HD, 814–823
  visfatin association with inflammation in, 237–244
Epidemiology, of chronic kidney disease in Taiwan, 46–55
Erythropoiesis-stimulating proteins, for iron deficiency in nondialysis-dependent CKD, 736–743
Exercise capacity, decreased in CHD patients, cystatin C levels and, 365–372

Familial cold autoinflammatory syndrome, with renal amyloidosis, IL-1 receptor antagonist for, 477–481
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis, diagnosis of, 862–864
Family history, Alagille syndrome diagnosis during adulthood, 705–709
Family members, offspring of hypertensive individuals, insulin resistance and sodium sensitivity in, 540–546
Females, prolonged CVC dependence in ESRD and, 276–283
Femoral catheters, soft silicone tunneled, for ARF, 99–108
Fenoldopam, meta-analysis of RCTs for acute renal failure, 56–68
Fetus, pregnancy outcome in stages 3-5 chronic kidney disease, 753–762
Fibrates, effect on arterial function in chronic kidney disease, 776–785
Fibrillary glomerulopathy, with hepatitis C, 717–720
Fibrinogen, coronary events in metabolic syndrome with CKD and, 356–364
Fibrosis, in encapsulating peritoneal sclerosis, peritoneal mast cells and, 452–461
Flank pain, with venous thrombosis from cocaine abuse, 859–861
Fluconazole, membranous nephropathy associated with, 318–322
Focal segmental glomerulosclerosis
  in cigarette smokers, 552–559
  sirolimus-associated nephrotoxicity and, 310–317
Forearm vein destruction, Gracz fistula for hemodialysis with, 824–830
Fractures in ESRD, lower bone mineral density and, 674–681

Gallium scan, long-term outcome prednisone therapy for idiopathic retropertioneal fibrosis, 615–625
Gastrointestinal lipase inhibitor, acute oxalate nephropathy associated with, 153–157
Gemfibrozil, effect on arterial function in CKD, 776–785
Genetic mutations. *See* Mutations
Genitourinary anomalies, small glomeruli in WAGR syndrome, 793–800
Genome scan, in West Africans for renal function in type 2 diabetes, 394–400
German Diabetes and Dialysis study, effects of dialyzer membrane characteristics on outcome for type 2 diabetes maintenance HD patients, 267–275
GFR. *See* Glomerular filtration rate
Gitelman syndrome
  hypotension, autonomic nervous function in, 330–335

nephrolithiasis with hypomagnesemia, 862–864
role of blood volume in hypocalciuria in, 693–700
Glomerular filtration rate (GFR)
decrease in living kidney donors, 143–152
estimated, effect of reporting on CKD care in outpatient clinics, 634–641
genome scan in West Africans for linkage of renal function phenotypes with type 2 diabetes, 394–400
in focal segmental glomerulosclerosis, sirolimus therapy and, 310–317
posttransplantation anemia not solely attributed to impaired kidney function, 301–309
variability in CKD with diastolic heart failure, left ventricular geometry and, 227–236
vs. cytostatin C in predicting impaired kidney function in CHD, 365–372
Glomeruli
in lupus nephritis, high levels of complement C3a receptor in, 598–606
small, in WAGR syndrome, 793–800
Glomerulonephritis
cryoglobulinemic, hepatitis C virus-related, 69–82
fibrillary, with hepatitis C, 717–720
rapidly progressive, 59-kd renal antigen target for, 710–716
Glomerulosclerosis, focal segmental, sirolimus-associated nephrotoxicity and, 310–317
Glucose, fasting plasma, survival of peritoneal dialysis patients and, 524–532
Goodpasture disease, 59-kd renal antigen target for, 710–716
gp130 expression, local activation of IL-6 in arteriovenous fistula stenosis and, 664–673
Gracz fistula, for hemodialysis, 824–830
Graft failure
mimicked by veno-calceal fistula related to ureteric structure, 547–551
survival of dialysis patients after, 294–300
Graft survival prediction, by recipient risk score for deceased donor kidney allocation, 284–293
Growth hormone deficiency, biallelic mutations in chloride channel gene *CLCNKB* and, 91–98
Growth retardation, biallelic mutations in chloride channel gene *CLCNKB* and, 91–98

Haplotype of *CRP* gene, CRP serum levels and, 118–126
HD. *See* Hemodialysis
Heart disease. *See* Cardiovascular disease
Heart morphology, renal function in diastolic heart failure with chronic kidney disease and, 227–236
Heart rate recovery, in CHD, cytostatin C levels and, 365–372
Hematocrit, rHuEPO dose reduction practices and, 135–142
Hemodialysis (HD). *See also* Dialyzer membranes; Maintenance hemodialysis
arteriovenous fistula stenosis, local activation of IL-6 and, 664–673
asymptomatic patients, distribution of coronary artery disease in relation to mortality, 409–416
cognitive impairment in, 183–185
diuretic usage, residual renal function, mortality and, 426–431
for children, intravenous paricalcitol therapy secondary hyperparathyroidism, 814–823
for ESRD
complication rate after pacemaker implantation, 656–663
lower bone mineral density in patients with fractures, 674–681
KDOQI guideline impact on mineral metabolism in, 257–266
long-term
for CKD, early development of, 482–496
survival on, 471–476
postponement, safety and efficacy of very low-protein diet in elderly and, 569–580
radial artery-perforating vein fistula for, 824–830
relationship between clinical performance measures and outcomes, 352–355
rHuEPO dose reduction practices in patients with elevated hemoglobin, 135–142
Staphylococcus aureus bacteremia with tunneled catheters, aspirin-associated decrease in, 401–408
subclinical vitamin K deficiency in, 432–439
total plasma homocysteine clearance, effect of IV mensa on, 109–117
vascular access. *See* Vascular access
Hemoglobin
posttransplantation anemia, not solely attributed to impaired kidney function, 301–309
rHuEPO dose reduction practices and, 135–142
target level for correction of anemia in diabetes, 194–207
Hemolytic-uremic syndrome, atypical, MCP mutation and uniparental isodisomy in, 323–329
Heparin, AN69ST membranes *vs.* regional anticoagulation in patients with bleeding risk, 642–649
Hepatitis C
cryoglobulinemic glomerulonephritis, multicenter study on, 69–82
with nephrotic syndrome, 717–720
Herbal therapy
CKD risk in adults not using analgesics, 626–633
use by chronic renal insufficiency patients, 245–256
Histological classification, for evaluating long-term renal survival factors in immunoglobulin A nephropathy, 763–775
Histology, small glomeruli in WAGR syndrome, 793–800
Historical perspective
development of long-term hemodialysis for chronic renal failure, 482–496
on uroscopy, 865–872
Homeopathic therapy
CKD risk in adults not using analgesics, 626–633
use by chronic renal insufficiency patients, 245–256
Homocysteine, total plasma clearance during HD, effect of IV mensa on, 109–117
Hospital care, use of DNR orders for kidney disease patients with AMI, 83–90
Hyperaldosteronism. *See also* Bartter syndrome
primary, prevalence and physiological consequences of, 566–568

Hyperammonemia, portosystemic encephalopathy in PD patient, 854–858
Hyperglycemia
management in chronic kidney disease, S2:62–73
new-onset in nondiabetic Chinese PD patients, 524–532
Hyperparathyroidism, secondary
in ESRD, cost utility analysis of cinacalcet *vs.* parathyroidectomy for, 801–813
IV paricalcitol therapy for children on hemodialysis, 814–823
Hypertension
and diabetes management in chronic kidney disease, S2:74–87
bevacizumab-associated, 186–193
blood pressure goals in controlling proteinuria, 12–26
in collagenofibrotic glomerulopathy, 499–506
in parent, insulin resistance and sodium sensitivity of offspring and, 540–546
in pregnancy with kidney disease, nephrology core curriculum for, 336–345
primary aldosteronism prevalence in, 566–568
renal lesions, mimicked by nodular glomerulosclerosis in cigarette smokers, 552–559
with diastolic heart failure and chronic kidney disease, left ventricular geometry and, 227–236
Hypertensive nephrosclerosis with diastolic heart failure, left ventricular geometry and, 227–236
Hypocalciuria, in Gitelman syndrome, blood volume and, 693–700
Hypoparathyroidism, secondary, minimodeling reduces rate of cortical bone loss in, 440–451
Hypotension, in Bartter/Gitelman syndromes, autonomic nervous function and, 330–335
Hypovolemia, hypocalciuria in Gitelman syndrome and, 693–700

Idiopathic retropertioneal fibrosis, long-term outcome with prednisone therapy, 615–625
Immunoglobulin A nephropathy, histological classification for evaluating long-term renal survival factors, 763–775
Incidence, of chronic kidney disease in Taiwan, 46–55
Infants, use of multipurpose drainage catheter for acute peritoneal dialysis, 650–655
Inflammation
impact of standard high-flux polysulfone *vs.* Helixone membranes on, 533–539
in CKD, visfatin associated with, 237–244
local activation of IL-6, arteriovenous fistula stenosis and, 664–673
synergistic effect with metabolic syndrome in CKD, 356–364
Insulin resistance, and sodium sensitivity in normotensive offspring of hypertensive individuals, 540–546
Interleukin 1 receptor antagonist, for renal amyloidosis in familial cold autoinflammatory syndrome, 477–481
Interleukin-6, local activation, arteriovenous fistula stenosis and, 664–673
Iron deficiency, treatment in nondialysis-dependent CKD, 736–743

JAK2/STAT3, local activation of IL-6 in arteriovenous fistula stenosis and, 664–673

Kaposi sarcoma, biomarkers of rapamycin sensitivity in, 462–470
KDOQI. *See* Kidney Disease Outcomes Quality Initiative
KEEP (Kidney Early Evaluation Program), annual data report for 2006, S3:1–160
Kidney Disease Outcomes Quality Initiative (KDOQI)
Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease, impact of, 257–266
Clinical Practice Guidelines, for Diabetes and Chronic Kidney Disease, S2:1–178
Kidney disease, with acute myocardial infarction, use of DNR orders for, 83–90
Kidney donation
deceased
allocation of, 180–182
recipient risk score for allocation of, 284–293
living, GFR decrease and coronary artery calcification in, 143–152
Kidney Early Evaluation Program (KEEP), annual data report for 2006, S3:1–160
Kidney function
impairments
associated with Orlistat, 153–157
contribution to morbidity and mortality in burn patients, 517–523
in propylthiouracil-associated ANCA-positive vasculitis, 607–614
posttransplantation anemia not solely attributed to, 301–309
small glomeruli in WAGR syndrome and, 793–800
with decreased HHR and exercise capacity, cytostatin C levels and, 375–372
in diabetes
genome scan for linkage regions in West Africans, 394–400
target level for hemoglobin correction of anemia in, 194–207
Kidney transplantation. *See also* Kidney donation
anemia not solely attributed to impaired kidney function, 301–309
cancer incidence before and after, 732–735
recipients
liver cyst rupture into pericardium with polycystic kidney disease, 851–853
veno-calceal fistula related to ureteric structure in kidney allograft dysfunction, 547–551
with Kaposi sarcoma, biomarkers of rapamycin sensitivity in, 462–470
survival of post-graft failure dialysis patients, 294–300
Kt/V ratio, soft silicone tunneled femoral dialysis catheters for ARF and, 99–108

LDL (low-density lipoprotein), reclassifying CKD as CHD risk equivalent, 8–11, 37–45
Left ventricular hypertrophy, target level for hemoglobin correction for anemia in diabetes, 194–207

Left ventricular mass index, chronic kidney disease with diastolic heart failure and, 227–236
Lipid-lowering treatment, reclassifying CKD as CHD risk equivalent, 8–11, 37–45
Liver cysts
in ADPKD, percutaneous transcatheter hepatic artery embolization for, 744–752
rupture into pericardium in kidney transplant recipient with polycystic kidney disease, 851–853
Low-density lipoprotein (LDL), reclassifying CKD as CHD risk equivalent, 8–11, 37–45
Lupus nephritis glomeruli, high levels of complement C3a receptor in, 598–606

Maintenance hemodialysis
mortality, abdominal aortic calcification and, 412–425
outcome of type 2 diabetes patients, effects of dialyzer membrane characteristics on, 267–275
Mast cells, peritoneal, fibrosis in encapsulating peritoneal sclerosis and, 452–461
Medical decision analysis, cinacalcet *vs.* parathyroidectomy for hyperparathyroidism in ESRD, 801–813
Membrane cofactor protein mutations, severity of atypical hemolytic-uremic syndrome and, 323–329
Membranoproliferative glomerulonephritis, hepatitis C virus-related, multicenter study on, 69–82
Membranous nephropathy, associated with fluconazole, 318–322
Mensa, total plasma homocysteine clearance during hemodialysis and, 109–117
Mental retardation, small glomeruli in WAGR syndrome, 793–800
Mesangium, type III collagen fibrils in collagenofibrotic glomerulopathy, 499–506
Meta-analyses
of bone mineral density in ESRD fracture patients, 674–681
of RCTs of fenoldopam for acute renal failure, 56–68
recommendations for reporting, 5
Metabolic syndrome, synergistic effects with inflammation in CKD, 356–364
Methicillin-resistant *Staphylococcus aureus* bacteremia, in HD patients with tunneled catheters, aspirin-associated decrease in, 401–408
Minerals
intake of Chinese patients during CAPD, cardiac disease and, 682–692
metabolism, impact of KDOQI guidelines on hemodialysis patients, 257–266
Minimal change nephrotic syndrome
in children, long-term outcome after cyclophosphamide, 592–597
rituximab efficacy in, 158–161
Minority populations, with chronic kidney disease and diabetes mellitus, S2:120–130
Mixed cryoglobulinemia, hepatitis C virus-related, multicenter study on, 69–82
Morbidity
catheter-related, soft silicone tunneled femoral dialysis catheters for ARF and, 99–108
postponement of dialysis, safety and efficacy of very low-protein diet for elderly, 569–580
Mortality, all-cause. *See also* Cardiovascular mortality
abdominal aortic calcification in maintenance hemodialysis and, 412–425
acute kidney injury in burn patients and, 517–523
early, intermediate and long-term risk factors in ESRD, 831–840
in chronic renal insufficiency, secondary prevention by simvastatin, 373–382
inflammation and metabolic syndrome in CKD and, 356–364
lower body mass index in men with CKD not yet on dialysis and, 581–591
nondialysis CKD patients, cardiac troponin I increase and, 507–516
of dialysis patients after primary graft failure, 294–300
outcome of maintenance hemodialysis for type 2 diabetes patients, effects of dialyzer membrane characteristics on, 267–275
postponement of dialysis, safety and efficacy of very low-protein diet for elderly, 569–580
prediction in spinal cord injury patients, kidney disease and, 383–393
Multirelapsing nephrotic syndrome, rituximab efficacy in, 158–161
Mutations
Anion exchanger 1 gene, in distal renal tubular acidosis of children from Thailand, 841–850
biallelic, in chloride channel gene *CLCNKB* and, 91–98
membrane cofactor protein, severity of atypical HUS and, 323–329
Myocardial infarction with kidney disease, use of DNR orders for, 83–90
Myocardial ischemia, platelet FcgRIIA receptor surface expression in ESRD and, 127–134

National Cholesterol Education Adult Treatment Panel III (ATP III), CHD risk equivalent, 8–11
Natural products. *See* Homeopathic therapy
Nephrolithiasis, with hypomagnesemia, inherited causes of, 862–864
Nephrology core curriculum
chronic kidney disease, 162–171
pregnancy: kidney disease and hypertension, 336–345
Nephrotic syndrome, with hepatitis C, 717–720
Nephrotoxicity, sirolumus-associated in focal segmental glomerulosclerosis, 310–317
Net life survival benefit (NLSB), allocation of deceased donor kidneys and, 180–182
Nodular glomerulosclerosis, in cigarette smokers, 552–559
Nonprescription medications. *See* Over-the-counter medications
Nonrandomized trials, recommendations for reporting, 3
Nutritional interventions, for diabetes and chronic kidney disease, 144–147, S2:95–107

Observational studies, recommendations for reporting, 3–4
Orlistat, acute oxalate nephropathy associated with, 153–157
Osteocalcin g-carboxylation, subclinical vitamin K deficiency in hemodialysis patients and, 432–439

Outcome
effect of statin and fibrate therapy on arterial function in chronic kidney disease, 776–785
fetal and maternal for pregnancy in CKD stages 3 to 5, 753–762
long-term
after cyclophosphamide for children with minimal change nephrotic syndrome, 592–597
hemodialysis, relationship to clinical performance measures, 352–355
on prednisone therapy for idiopathic retropertioneal fibrosis, 615–625
postponement of dialysis, safety and efficacy of very low-protein diet for elderly, 569–580
Over-the-counter medications, usage by chronic renal insufficiency patients, 245–256
Oxalate nephropathy, associated with Orlistat, 153–157
Oxidative stress, impact of standard high-flux polysulfone *vs.* Helixone membranes on inflammatory markers, 533–539

P70 S6 kinase, as rapamycin sensitivity biomarker in renal transplant recipients with Kaposi sarcoma, 462–470
Pacemaker implantation, complication rate in ESRD patients, 656–663
Parathyroid hormone (PTH)
cinacalcet *vs.* parathyroidectomy for hyperparathyroidism in ESRD, 801–813
impact of KDOQI guidelines on hemodialysis patients, 257–266
Parathyroidectomy, *vs.* cinacalcet-based therapy for hyperparathyroidism in ESRD, 801–813
Paricalcitol, for secondary hyperparathyroidism in children on hemodialysis, 814–823
Patient outcome. *See* Outcome
PD. *See* Peritoneal dialysis
Pericardium, liver cyst rupture, in kidney transplant recipient with polycystic kidney disease, 851–853
Peritoneal dialysis (PD)
multipurpose drainage catheter for infants and children, 650–655
nondiabetic Chinese, new-onset hyperglycemia in, 524–532
nutrient intake of Chinese patients, cardiac disease and, 682–692
peritoneal mast cells in encapsulating peritoneal sclerosis and, 452–461
portosystemic encephalopathy in, 854–858
postponement, safety and efficacy of very low-protein diet in elderly and, 569–580
Peritonitis, *Aspergillus oryzae,* in continuous ambulatory peritoneal dialysis, 701–704
Phosphate, impact of KDOQI guidelines on hemodialysis patients, 257–266
Phylloquinone, subclinical vitamin K deficiency in hemodialysis patients and, 432–439
Platelet FcgRIIA receptor surface expression, in end-stage renal disease, 127–134
Polycystic liver disease (PLD)
cyst rupture into pericardium of kidney transplant recipient with polycystic kidney disease, 851–853
percutaneous transcatheter hepatic artery embolization for, 744–752
symptoms and treatments for, 725–728
Portosystemic encephalopathy, in peritoneal dialysis patient, 854–858
Potassium wasting disorder. *See* Bartter syndrome
Practice patterns in hemodialysis, diuretic usage, residual renal function, mortality and, 426–431
Pre-B-cell colony-enhancing factor 1, CKD associated with inflammation, 237–244
Prednisone, for idiopathic retropertioneal fibrosis, long-term outcome from, 615–625
Pregnancy
chronic kidney disease and, 729–731
fetal and maternal for outcomes with chronic kidney disease, 753–762
with kidney disease and hypertension, nephrology core curriculum for, 336–345
Prevalence, of chronic kidney disease in Taiwan, 46–55
Progression of kidney disease, fetal and maternal for outcomes in pregnancy with chronic kidney disease, 753–762
Propylthiouracil, ANCA-positive vasculitis associated with, 607–614
Proteinuria
antihypertensive therapy for, 12–26
bevacizumab-associated, 186–193
biallelic mutations in chloride channel gene *CLCNKB* and, 91–98
fetal and maternal for outcomes in pregnancy with CKD, 753–762
in fluconazole-associated membranous nephropathy, 318–322
in focal segmental glomerulosclerosis, sirolimus therapy and, 310–317
in nephrotic syndrome with hepatitis C, 717–720
prediction of mortality in spinal cord injury patients and, 383–393
Pseudo renal failure, veno-calceal fistula related to ureteric structure in kidney allograft dysfunction, 547–551
PTH. *See* Parathyroid hormone

Quality of life, target level for hemoglobin correction of anemia in diabetes, 194–207

Race, prolonged CVC dependence in ESRD and, 276–283
Randomized controlled trials
meta-analysis of fenoldopam for acute renal failure, 56–68
recommendations for reporting, 3
Rapamycin sensitivity in Kaposi sarcoma, biomarkers of, 462–470
Recombinant human erythropoietin (rHuEPO), dose reduction practices, 135–142
Remodeling, cortical bone loss in secondary hypoparathyroidism reduced by, 440–451
Renal replacement therapy. *See also* Hemodialysis; Peritoneal dialysis
contribution of acute kidney injury to morbidity and morality in burn patients and, 517–523

impact of fenoldopam for acute renal failure in critically ill patients, 56–68
supplemental very low protein diet as temporary alternative for, 563–565
Renovascular disease, Alagille syndrome diagnosis during adulthood, 705–709
Residual renal function, in hemodialysis patients, diuretic usage and, 426–431
rHuEPO (recombinant human erythropoietin), dose reduction practices, 135–142
RIFLE classification, prognosis for burn patients with acute kidney injury, 517–523
Risk factors, early, intermediate and long-term for mortality in ESRD, 831–840
Rituximab, efficacy in minimal change disease, 158–161

Salicylic acid, decreased frequency of *Staphylococcus aureus* bacteremia in HD patients with tunneled catheters, 401–408
Scientific Registry of Transplant Recipients (SRTR), survival of post-graft failure dialysis patients, 294–300
Simvastatin, for secondary prevention of all-cause mortality and coronary events in chronic renal insufficiency, 373–382
Sirolimus, for focal segmental glomerulosclerosis associated with nephrotoxicity, 310–317
Social class, chronic kidney disease risk and, 217–226
Socioeconomic status, chronic kidney disease risk and, 217–226
Sodium sensitivity, and insulin resistance in normotensive offspring of hypertensive individuals, 540–546
Southeast Asian ovalocytosis, with distal renal tubular acidosis in children, *AE1* gene mutations and, 841–850
Spinal cord injury, mortality prediction, kidney disease and, 383–393
SRTR (Scientific Registry of Transplant Recipients), survival of post-graft failure dialysis patients, 294–300
Staphylococcus aureus bacteremia, in HD patients with tunneled catheters, aspirin-associated decrease in, 401–408
Statins
effect on arterial function in chronic kidney disease, 776–785
for secondary prevention of all-cause mortality and coronary events in chronic renal insufficiency, 373–382
Statistics, recommendations for reporting, 5–6
Subendothelial space, type III collagen fibrils in collagenofibrotic glomerulopathy, 499–506
Surrogate molecular markers, of rapamycin sensitivity in renal transplant recipients with Kaposi sarcoma, 462–470
Survival
long-term
early, intermediate and long-term risk factors for mortality in ESRD, 831–840
histological classification for evaluating in immunoglobulin A nephropathy, 763–775
on hemodialysis, 471–476
posttransplant, of post-graft failure dialysis patients, 294–300
soft silicone tunneled femoral dialysis catheters for ARF and, 99–108
Systematic reviews, recommendations for reporting, 5

Taiwan
CKD risk in adults on herbal therapy not using analgesics, 626–633
epidemiology of chronic kidney disease in, 46–55
Thailand children, with distal renal tubular acidosis associated with *AE1* gene mutations, 841–850
Third National Cholesterol Education Program Adult Treatment Panel (ATP-III), CHD equivalent, 8–11
Thrombotic microangiopathy, renal lesions mimicked in cigarette smokers, 552–559
Transcatheter hepatic artery embolization, for liver cysts in ADPKD, 744–752
Treatment outcome. *See* Outcome
Tryptase, in peritoneal mast cells in encapsulating peritoneal sclerosis PD patients, 452–461
Tunneled catheters
soft silicone femoral for ARF, 99–108
Staphylococcus aureus bacteremia risk in HD patients, aspirin-associated decrease in, 401–408
Type III collagen, in collagenofibrotic glomerulopathy, 499–506

UACR (urinary albumin-creatinine ratio), risk of CVD and death in American Indians with normal range values, 208–216
Uniparental isodisomy, severity of atypical hemolytic-uremic syndrome and, 323–329
United States Renal Data System, Annual Data Report 2006, S1:1–194
Uremia, enhanced platelet FcgRIIA receptor surface expression in end-stage renal disease and, 127–134
Ureteric obstruction, veno-calceal fistula development in kidney allograft dysfunction, 547–551
Urinary albumin-creatinine ratio (UACR), risk of CVD and death in American Indians with normal range values, 208–216
Uroscopy, historical perspective on, 865–872

Vascular access
arteriovenous fistula for. *See* Arteriovenous fistula
long-term survival on hemodialysis, 471–476
predictors of delayed transition to permanent vascular access in ESRD, 276–283
radial artery-perforating vein fistula for hemodialysis, 824–830
veno-calceal fistula, related to ureteric structure in kidney allograft dysfunction, 547–551
Vascular calcification, in living kidney donors, decreased GFR and, 143–152
Vascular cell adhesion molecule-1, visfatin levels in chronic kidney disease and, 237–244
Vascular endothelial growth factor, targeting by bevacizumab, risk of proteinuria and hypertension with, 186–193
Vegan diet. *See* Very low protein diet
Veno-calceal fistula, related to ureteric structure in kidney allograft dysfunction, 547–551
Venous thrombosis, and loin pain from cocaine abuse, 859–861

Very low protein diet (VLPD)
as temporary alternative to renal replacement therapy, 563–565
safety and efficacy for postponement of dialysis elderly, 569–580
Visfatin, inflammation in CKD and, 237–244
Vitamin B intake, of Chinese patients during CAPD, cardiac disease and, 682–692
Vitamin K, subclinical deficiency in hemodialysis patients, 432–439
VLPD. *See* Very low protein diet

WAGR syndrome, small glomeruli in, 793–800
West Africans, genome scan for linkage of renal function phenotypes with type 2 diabetes, 394–400
Wilms tumor suppressor gene, small glomeruli in WAGR syndrome, 793–800
World Kidney Day, focus on chronic kidney disease, 175–179